Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41591-021-01386-7 http://scihub22266oqcxt.onion/10.1038/s41591-021-01386-7 34017137!8291091!34017137     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nat+Med 2021 ; 27 (7): 1280-1289 Nephropedia Template TP {{tp|p=34017137|t=2021. CD8(+) T cells contribute to survival in patients with COVID-19 and hematologic cancer |pdf=|usr=}}{{34017137}} gab.com Text CD8(+) T cells contribute to survival in patients with COVID-19 and hematologic cancer JO: Nat Med http://www.kidney.de/pget.php?&tw=1&pmid=34017137 #FOAvip Patients with cancer have high mortality from coronavirus disease 2019 (COVID-19), and the immune parameters that dictate clinical outcomes remain unknown. In a cohort of 100 patients with cancer who were hospitalized for COVID-19, patients with hematologic cancer had higher mortality relative to patients with solid cancer. In two additional cohorts, flow cytometric and serologic analyses demonstrated that patients with solid cancer and patients without cancer had a similar immune phenotype during acute COVID-19, whereas patients with hematologic cancer had impairment of B cells and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibody responses. Despite the impaired humoral immunity and high mortality in patients with hematologic cancer who also have COVID-19, those with a greater number of CD8 T cells had improved survival, including those treated with anti-CD20 therapy. Furthermore, 77% of patients with hematologic cancer had detectable SARS-CoV-2-specific T cell responses. Thus, CD8 T cells might influence recovery from COVID-19 when humoral immunity is deficient. These observations suggest that CD8 T cell responses to vaccination might provide protection in patients with hematologic cancer even in the setting of limited humoral responses. Twit Text FOAVip CD8(+) T cells contribute to survival in patients with COVID-19 and hematologic cancer ????Nat Med http://www.kidney.de/pget.php?&tw=1&pmid=34017137 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34017137 #FOAvip English Wikipedia <ref>{{Cite pmid|34017137}}</ref> CD8(+) T cells contribute to survival in patients with COVID-19 and hematologic cancer #MMPMID34017137 Bange EM; Han NA; Wileyto P; Kim JY; Gouma S; Robinson J; Greenplate AR; Hwee MA; Porterfield F; Owoyemi O; Naik K; Zheng C; Galantino M; Weisman AR; Ittner CAG; Kugler EM; Baxter AE; Oniyide O; Agyekum RS; Dunn TG; Jones TK; Giannini HM; Weirick ME; McAllister CM; Babady NE; Kumar A; Widman AJ; DeWolf S; Boutemine SR; Roberts C; Budzik KR; Tollett S; Wright C; Perloff T; Sun L; Mathew D; Giles JR; Oldridge DA; Wu JE; Alanio C; Adamski S; Garfall AL; Vella LA; Kerr SJ; Cohen JV; Oyer RA; Massa R; Maillard IP; Maxwell KN; Reilly JP; Maslak PG; Vonderheide RH; Wolchok JD; Hensley SE; Wherry EJ; Meyer NJ; DeMichele AM; Vardhana SA; Mamtani R; Huang AC Nat Med 2021[Jul]; 27 (7): 1280-1289 PMID34017137show ga Patients with cancer have high mortality from coronavirus disease 2019 (COVID-19), and the immune parameters that dictate clinical outcomes remain unknown. In a cohort of 100 patients with cancer who were hospitalized for COVID-19, patients with hematologic cancer had higher mortality relative to patients with solid cancer. In two additional cohorts, flow cytometric and serologic analyses demonstrated that patients with solid cancer and patients without cancer had a similar immune phenotype during acute COVID-19, whereas patients with hematologic cancer had impairment of B cells and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibody responses. Despite the impaired humoral immunity and high mortality in patients with hematologic cancer who also have COVID-19, those with a greater number of CD8 T cells had improved survival, including those treated with anti-CD20 therapy. Furthermore, 77% of patients with hematologic cancer had detectable SARS-CoV-2-specific T cell responses. Thus, CD8 T cells might influence recovery from COVID-19 when humoral immunity is deficient. These observations suggest that CD8 T cell responses to vaccination might provide protection in patients with hematologic cancer even in the setting of limited humoral responses. |Aged[MESH] |Antibodies, Viral/immunology[MESH] |B-Lymphocytes/immunology[MESH] |CD8-Positive T-Lymphocytes/*immunology[MESH] |COVID-19/complications/*immunology/mortality[MESH] |Cohort Studies[MESH] |Female[MESH] |Hematologic Neoplasms/complications/*immunology[MESH] |Humans[MESH] |Immunity, Cellular/immunology[MESH] |Immunity, Humoral/immunology[MESH] |Immunophenotyping[MESH] |Logistic Models[MESH] |Male[MESH] |Middle Aged[MESH] |Multivariate Analysis[MESH] |Neoplasms/complications/*immunology[MESH] |Proportional Hazards Models[MESH] |Prospective Studies[MESH] |SARS-CoV-2[MESH]CD8(+) T cells contribute to survival in patients with COVID-19 and he(epmc).pdf DeepDyve Pubget Overpricing